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RESUMO
Impacto Clínico da Isquemia e Viabilidade 
Miocárdicas após Tratamento de Oclusão Coronária 
Crônica no Segmento Proximal da Artéria 
Descendente Anterior
Introdução: A avaliação da isquemia e viabilidade miocárdicas 
é recomendável antes da intervenção coronária percutânea (ICP) 
em oclusões crônicas. Avaliamos os eventos cardiovasculares 
adversos tardios de pacientes com ICP da oclusão crônica no 
segmento proximal da artéria descendente anterior, comparando 
pacientes de acordo com a presença ou não de isquemia ou 
viabilidade miocárdicas. Métodos: Os pacientes foram aloca-
dos nos grupos com isquemia/viabilidade miocárdicas (G1, n 
= 91) e sem isquemia/viabilidade miocárdicas (G2, n = 65) e 
avaliados os eventos clínicos combinados tardios (óbito, infarto 
do miocárdio, revascularização do vaso-alvo e insuficiência 
cardíaca congestiva). Resultados: A maioria dos pacientes era 
do sexo masculino (68,1% vs. 69,2%; P = 0,56), com média 
de idade de 65,4 ± 10,4 anos vs. 63,5 ± 8,7 anos (P = 0,61), 
e quase um terço era de diabéticos (33% vs. 29,2%; P = 
0,76). Os grupos não mostraram diferenças em relação ao 
perfil clínico-angiográfico, com exceção da fração de ejeção 
do ventrículo esquerdo (48,6 ± 13,7% vs. 39,5 ± 11,8%; P = 
0,04) e do grau de circulação colateral para a artéria descen-
dente anterior, mais evidente no G1 (P = 0,03). A incidência 
de eventos clínicos combinados em um período de três anos 
foi menor nos pacientes com isquemia/viabilidade miocárdicas 
ABSTRACT
Background: Evaluation of myocardial ischemia and viability 
is recommended prior to percutaneous coronary intervention 
(PCI) for chronic total occlusions. We evaluated late adverse 
cardiovascular events of patients with PCI for proximal left 
anterior descending artery occlusions, comparing patients 
with or without myocardial ischemia or viability. Methods: 
Patients were allocated to groups with myocardial ischemia/
viability (G1, n = 91) and without myocardial ischemia/
viability (G2, n = 65) and adverse cardiovascular events 
(death, myocardial infarction, target-vessel revasculariza-
tion and congestive heart failure) were compared. Results: 
Most patients were male (68.1% vs 69.2%; P = 0.56), with 
a mean age of 65.4 ± 10 years vs 63.5 ± 8.7 years (P = 
0.61) and almost one third were diabetics (33% vs 29.2%; 
P = 0.76). No differences regarding the clinical and angio-
graphic profile were observed, except for the left ventricular 
ejection fraction (48.6 ± 13.7% vs 39.5 ± 11.8%; P = 0.04) 
and the degree of angiographic collateral flow grade to the 
left anterior descending artery, which was more evident 
in G1 (P = 0.03). The 3-year follow-up incidence of com-
posite adverse cardiovascular events was lower in patients 
with myocardial ischemia/viability (12.5% vs 31.1%; P < 
0.01). The factors that contributed the most for this differ-
ence were the incidence of congestive heart failure (3.3% 
vs 15.3%; P = 0.02) and death (2.2% vs 7.7%; P = 0.13). 
Conclusions: Treatment of proximal left anterior descending 
artery chronic total occlusions in patients with evidence of 
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myocardial ischemia or viability reduces the incidence of 
adverse cardiovascular events in the long term.
 
 
 
 
 
DESCRIPTORS: Angioplasty. Drug-eluting stents. Coronary 
occlusion. Coronary angiography.
This study aimed to analyze the long-term results 
of patients successfully treated by percutaneous re-
canalization of chronic coronary occlusion with DES 
implantation in the left anterior descending artery 
proximal segment, comparing two different populations 
according to the presence or absence of ischemia or 
myocardial viability, related to the occurrence of late 
adverse cardiovascular events.
METHODS
Patients
From January 2001 to December 2012, 269 patients 
with chronic coronary occlusion in the left anterior 
descending artery proximal segment were treated in 
this hospital. Patients whose initial clinical presenta-
tion was acute myocardial infarction with ST-segment 
elevation or previous CABG were excluded. Of the 235 
(87.4%) successfully treated patients, 156 (66.4%) had 
undergone ischemia and myocardial viability assess-
ment. These patients were allocated into groups with 
ischemia/myocardial viability (G1, n = 91) or without 
ischemia/myocardial viability (G2, n = 65). 
The study was performed according to the Declara-
tion of Helsinki regarding research in human subjects 
and all patients signed an informed consent.
Percutaneous coronary intervention
Percutaneous coronary interventions (PCIs) were 
performed in accordance with the current guide-
lines,12-14 and the final procedure strategy was left to 
the surgeon’s discretion. In all patients, recanalization 
of the left anterior descending artery was performed 
by anterograde approach, and in 67 patients (42.9%) 
right and left coronary artery angiography were per-
formed simultaneously. These lesions were treated with 
DES, which did not occur with the additional vessels 
in patients with multivessel disease, who received 
DES or BMS.
During the procedure, unfractionated heparin was 
administered at a dose of 70  IU/kg to 100 IU/kg, and 
the use of IIb/IIIa glycoprotein inhibitors was left to the 
surgeon’s discretion. Pre-dilation was not mandatory, 
(12,5% vs. 31,1%; P < 0,01). Os fatores que mais contribuíram 
para essa diferença foram a incidência de insuficiência cardíaca 
congestiva (3,3% vs. 15,3%; P = 0,02) e óbito (2,2% vs. 7,7%; 
P = 0,13). Conclusões: O tratamento de oclusão crônica no 
segmento proximal da artéria descendente anterior com stent 
farmacológico, em pacientes com evidência de isquemia ou 
viabilidade miocárdicas, reduz eventos clínicos a longo prazo.
DESCRITORES: Angioplastia. Stents farmacológicos. Oclusão 
coronária. Angiografia coronária.
T he left anterior descending artery is responsible for irrigating most of the left ventricular musculature and, thus, severe atherosclerotic obstructive disease 
in its proximal segment is associated with worse prog-
nosis.1 The left anterior descending artery is a turning 
point among clinical, percutaneous, and surgical treat-
ments in obstructive coronary artery disease, especially 
when presenting as chronic coronary occlusion in its 
proximal segment.2 Even more challenging for several 
treatment modalities is the combination of chronic 
coronary occlusion of the left anterior descending 
artery and multivessel coronary disease, particularly 
in diabetic patients, in whom, in most cases, surgical 
treatment is preferred.2,3
Drug-eluting stents (DES) have shown significant 
reduction in restenosis and the need for a new inter-
vention when compared to bare-metal stents (BMS).4-6 
In the treatment of the left anterior descending artery 
proximal segment, it is notable the best clinical out-
comes of patients treated with DES, when compared 
with those treated with BMS,7 with a similar clinical 
outcome to that of patients undergoing coronary artery 
bypass graft (CABG) surgery using graft from the left 
internal mammary artery to the left anterior descending 
artery.8 Particularly in patients with chronic coronary 
occlusion,9,10 and specifically in the proximal segment 
of the left anterior descending artery,11 the beneficial 
effect of DES on clinical outcomes in the long-term when 
compared to patients receiving BMS is indisputable; 
DES is recommended by Brazilian12 and international 
guidelines.13,14
Currently, percutaneous revascularization is an 
excellent option in the management of chronic coro-
nary occlusion, but proper selection of patients and a 
careful assessment of the anatomical lesion aspects, the 
availability of devices dedicated to the management of 
occlusions, and the availability of DES are paramount. 
When selecting patients, it is recommended to evaluate, 
prior to procedure, the presence of ischemia and myo-
cardium viability, which is associated with ventricular 
dysfunction regression after the recovery of coronary 
flow to the cardiac muscle area irrigated by the ves-
sel.15,16 However, this recommendation is not always 
followed in daily clinical practice. 
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and stent post-dilatation was recommended in case of 
residual stenosis > 20 % by visual estimation.
Dual antiplatelet therapy consisted in the admin-
istration of 100 mg/day of acetylsalicylic acid and 75 
mg/day of clopidogrel. The administration of clopidogrel 
should be started at least 24 hours before the procedure, 
and a loading dose of 300 mg (or 600 mg if PCI < 24 
hours) was recommended. After the PCI, therapy with 
acetylsalicylic acid was maintained indefinitely thereafter, 
and clopidogrel was maintained for at least one year.
Ischemia and myocardial viability study
Two techniques for the assessment of ischemia and 
myocardial viability were used in the present study: 
– Cardiac magnetic resonance imaging,17 performed 
with contractile reserve assessment with inotropic 
stimulation with dobutamine and complemented with 
late enhancement with gadolinium. The increased thick-
ness of the myocardial wall induced by dobutamine 
is a good predictor of residual metabolic activity. The 
myocardial regions exhibiting delayed enhancement 
with gadolinium coincide with regions of myocardial 
necrosis and irreversible damage. Regions that do not 
exhibit this delayed enhancement are viable. 
– Stress echocardiography with dobutamine,18 
whose standard protocol consisted of a continuous 
infusion of dobutamine at an initial dose of 5 mcg/kg/
min, followed by 10  mcg/kg/min, 20 mcg/kg/min, 30 
mcg/kg/min, and 40 mcg/kg/min every 3 min. Atropine 
at fractionated doses of 0.5 mg, up to a total of 2 mg, 
could be administered, if necessary, to achieve the target 
heart rate (defined as 85% of the maximum heart rate 
calculated for age). The biphasic response, improved 
segmental contractility at lower doses of dobutamine 
and worsening with higher doses were considered 
indicative of myocardial viability and stress-induced 
ischemia, respectively.
The ischemia and myocardial viability were evalu-
ated by dobutamine-stress echocardiography in 51.3% 
and by cardiac nuclear magnetic resonance in 48.7% 
of patients.
Outcomes and clinical follow-up
The primary study outcome was the occurrence of 
composite clinical events in the late follow-up, defined 
as cardiac death, nonfatal myocardial infarction, target-
vessel revascularization, and congestive heart failure. 
All deaths were considered cardiac, unless a non-
cardiac cause could be clearly established by clinical 
and/or pathological study. The diagnosis of myocar-
dial infarction was based on the development of new 
pathological Q waves in > 2 contiguous ECG leads 
and/or elevation of CK-MB isoenzyme > three-fold the 
upper normal limit after the procedure during the index 
hospitalization, or > two-fold the upper normal limit after 
hospital discharge. All new revascularizations, whether 
surgical or percutaneous, were recorded.
Clinical follow-up was performed after the proce-
dure, and consisted of telephone contact performed 
according to a predefined institutional protocol. 
Statistical Analysis
Categorical variables were expressed as absolute 
numbers and percentages, and evaluated by chi-squared 
or Fisher exact tests when appropriate. Continuous vari-
ables were expressed as means and standard deviations 
and compared using Student’s t-test. P-values < 0.05 
were considered statistically significant.
RESULTS
The clinical and angiographic characteristics of 
patients are summarized in Table 1. Most patients were 
males (68.1 % vs. 69.2 %; P = 0.56), with a mean age 
of 65.4 ± 10.4 years vs. 63.5 ± 8.7 years (P = 0.61); 
almost one-third were diabetics (33% vs. 29.2%; P = 
0.76). Stable clinical pictures predominated, as well as 
multivessel coronary artery disease in the angiographic 
analysis. The groups did not present any differences, 
except for the left ventricular ejection fraction (48.6 ± 
13.7% vs. 39.5 ± 11.8%; P = 0.04) and the degree of 
angiographic collateral flow grade to the left anterior 
descending artery, more evident in G1 (P = 0.03).
DES were implanted in the left anterior descending 
artery in all patients; in multivessel disease patients, 
DES or BMS in the other coronary arteries. The DES 
implanted in the left anterior descending artery were, 
in two-thirds of cases (64.1%), sirolimus- or paclitaxel-
eluting stents, and in the others, everolimus-, zotarolimus-, 
or biolimus-eluting stents. In patients with two-vessel 
involvement, 234 lesions were treated with two or 
more stents in 76.9% of cases, and with one stent in 
the others. In patients with three-vessel involvement, 
390 lesions were treated with three or more stents in 
60.8% of cases, and two stents in the remaining.
The incidence of composite clinical events during a 
three-year period was lower in patients with ischemia/
myocardial viability (12.1% vs. 30.8 %; P < 0.01). The 
main factor that contributed to this difference was the 
incidence of congestive heart failure (3.3% vs. 15.3%; 
P = 0.02) and death (2.2% vs. 7.7%; P = 0.13). The 
other clinical events were similar between the groups. 
These data are presented in Table 2. Angiographic 
restenosis of the left anterior descending artery was 
detected in 6.6% vs. 6.2% (P > 0.99).
DISCUSSION
This study demonstrated the long-term benefit of 
chronic coronary occlusion treatment in the left an-
terior descending artery proximal segment with DES 
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TABLE 1  
Clinical and angiographic characteristics of patients
G1 (n = 91) G2 (n = 65) P-value
Age, years 65.4 ± 10.4 63.5 ± 8.7 0.61
Male gender, n (%) 62 (68.1) 45 (69.2) 0.56
Body mass índex, Kg/m2 26.9 ± 4.3 27.8 ± 4.5 0.11
Current smoking, n (%) 25 (27.5) 18 (27.7) 0.93
Hypertension, n (%) 50 (54.9) 33 (50.8) 0.77
Dyslipidemia, n (%) 55 (60.4) 37 (56.9) 0.88
Diabetes, n (%) 30 (33) 19 (29.2) 0.76
Insulin use 7 (7.7) 5 (7.7) > 0.99
Previous infarction, n (%) 69 (75.8) 50 (76.9) 0.88
Previous percutaneous coronary intervention, n (%) 6 (6.6) 5 (7.7) 0.86
Clinical presentation, n (%) 0.17
Stable angina 50 (54.9) 34 (52.3)
Unstable angina 26 (28.6) 19 (29.2)
Silent ischemia 24 (26.4) 12 (18.5)
Left ventricular ejection fraction 48.6±13.7 39.5 ± 11.8 0.04
Number of affected vessels, n (%) 0.88
One vessel 16 (17.6) 9 (13.8)
Two vessels 42 (46.2) 31 (47.7)
Three vessels 33 (36.2) 25 (38.5)
Collateral flow grade to the left anterior descending artery 0.03
1 or 2+ 36 (39.6) 35 (53.8)
3 or 4+ 55 (60.4) 30 (46.2)
Table 2  
Frequency of major adverse cardiovascular events in three years.
G1 (n = 91) G2 (n = 65) P-value
Death, n (%) 2 (2.2) 5 (7.7) 0.13
Myocardial infarction, n (%) 1 (1.1) 1 (1.5) > 0.99
New revascularization, n (%) 6 (6.6) 5 (7.7) > 0.99
Coronary artery bypass graft surgery, n (%) 2 2
Percutaneous coronary intervention, n (%) 4 3
Congestive heart failure, n (%) 3 (3.3) 10 (15.3) 0.02
Composite clinical events, n (%) 11 (12.1) 20 (30.8) < 0.01
in patients with evidence of ischemia or myocardial 
viability at the expense of a significant reduction in 
congestive heart failure episodes and non-significant 
decrease in mortality. Single-digit restenosis of the left 
anterior descending artery is compatible with results 
found in studies using similar DES,9 and it was a factor 
that did not affect the difference of composite clinical 
events between the two groups.
Biological and anatomical aspects are known as 
myocyte-protective factors in a possible coronary occlu-
sion: ischemic preconditioning and collateral circulation 
to the target vessel. The ischemic preconditioning is a 
biomolecular phenomenon that protects the myocytes 
through the occlusion and repeated reperfusion of a 
coronary artery, correcting, through complex mecha-
nisms intrinsic to the cardiac cell, and regardless of 
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the collateral circulation, the mitochondrial intracel-
lular adaptation to face the permanent ischemia due 
to vessel occlusion.19,20 The collateral circulation to 
the occluded vessel is undoubtedly a key anatomical 
factor in the overall or partial preservation of the heart 
muscle contractility in the area irrigated by the ves-
sel with chronic coronary occlusion.21,22 However, in 
order to be effective, this collateral circulation should 
be recruited early and effectively, providing blood 
flow to the occluded vessel.22 In the present patients, 
left ventricular function was better in the group with 
ischemia/myocardial viability when compared to the 
group without it, possibly associated with better irriga-
tion of the region.
Safley et al.23 evaluated 2,608 patients with one-
vessel chronic coronary occlusion, divided according the 
treated coronary: left anterior descending artery in 936 
cases (36%), left circumflex artery in 682 cases (26%), 
and right coronary artery in 990 (38%). Procedural 
success was obtained, respectively, in 77%, 76%, and 
72%. When comparing the five-year evolution in the 
three groups, a better clinical outcome was observed 
in patients who attained successful vs. unsuccessful 
recanalization of the left anterior descending artery 
(88.9 % vs. 80.2%; P < 0.001). This was not observed 
with the left circumflex artery (86.1 % vs. 82.1 %; P 
= 0.21) or right coronary artery (87.7% vs. 84.9%; P = 
0.23). The authors concluded that if the benefit occurs 
only in patients who attained success in the left anterior 
descending artery, it would be necessary to stringently 
select cases for PCI in patients with one-vessel chronic 
coronary occlusion. However, Mehran and Dangas,11 
in a corresponding editorial,23 argued that the absence 
of data regarding evaluation of ischemia/myocardial vi-
ability, among other considerations, may have affected 
the conclusions of that study.
Another important clinical aspect is the combination 
of chronic coronary occlusion of a major vessel with 
multivessel coronary artery disease. A recent report24 
demonstrated that, in this anatomical condition, the 
clinical importance of the complete revasculariza-
tion is essential for clinical symptom and survival 
improvement, particularly in patients with ischemia or 
myocardial viability. However, the complete functional 
revascularization has been proven to be as effective 
in preventing clinical events in the long-term as the 
full anatomical revascularization.25,26 The concept of 
functional percutaneous revascularization in patients 
with multivessel coronary artery disease was explored 
in the Fractional flow reserve versus Angiography in 
Multivessel Evaluation (FAME) study,27 in which the 
physiological-functional evaluation of coronary artery 
obstructive lesions using the fractional flow reserve re-
duced adverse clinical outcomes and operational costs. 
The fractional flow reserve started to be indicated in 
the North-American guideline14 as class I, level A of 
evidence, and in the European guideline,13 as class IIa, 
level A of evidence. In the present study, it was not 
possible to use fractional flow reserve, which certainly 
could add more precise functional information regard-
ing obstructive coronary lesions in the present patients 
with multivessel coronary artery disease.
The use of DES in the right coronary artery and 
left circumflex artery in patients with multivessel coro-
nary artery disease, in the present study, was directed 
to non-diabetic patients with focal lesions, in vessels 
with a diameter > 2.75 mm, which is in accordance 
with the methods and results of the Italian multicenter 
study.28 This strategy of using the DES and BMS side by 
side in patients with multivessel coronary artery disease, 
particularly the indication of these endoprostheses ac-
cording to the likelihood of lower or greater restenosis, 
still remains as a current conduct, legitimized, for 
instance, at the recently published Dutch study based 
on the criteria of the National Institute for Clinical 
Excellence (NICE).29
The present findings expand the knowledge regard-
ing the assessment of ischemia and myocardial viability 
before the percutaneous procedure in a specific popula-
tion of patients with chronic coronary occlusion of the 
left anterior descending artery proximal segment, treated 
with DES, adding this information to that obtained by 
other studies that presented similar results.24,30-32
Limitations of the study
This study has several limitations, including: 1) 
retrospective and single-center design, 2) small sample 
size, 3) fractional flow reserve was not used in the 
evaluation of lesions in patients with multivessel disease, 
4) clinical information was obtained in the long-term 
by telephone contact or with the attending physician.
CONCLUSIONS
The treatment of chronic coronary occlusion in 
the left anterior descending artery proximal segment 
with DES, in patients with evidence of ischemia or 
myocardial viability, reduces long-term clinical events. 
The choice of percutaneous revascularization depends 
on a number of factors, and must be based on adequate 
patient selection, careful evaluation of the anatomical 
aspects of the lesion, availability of devices dedicated to 
the management of occlusions, and availability of DES.
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